December 26, 2019
1 min read
Save
FDA approves generic travoprost
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The FDA has approved an abbreviated new drug application for travoprost ophthalmic solution 0.004%, Alembic Pharmaceuticals announced in a press release.
The solution is therapeutically equivalent to Travatan Ophthalmic Solution 0.004% (Alcon).
It is indicated for the treatment of open angle glaucoma or ocular hypertension.